| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| ln Vivo |
O-desmethylated encainide (MJ 9444) and 3-O-Effects of methoxyencainide (MJ 14030) on cardiac conduction in canine hearts following atrioventricular node disruption in vivo are the two main metabolites of encainib. When it came to decreasing conduction in the rabbit heart's atria, atrioventricular nodes, and His-Purkinje system, both metabolites were 4–15 times more effective than encainide. Encainide (0.8-3.2 mg/kg iv) prolongs the effective and functional refractory periods of the Purkinje pathway in dogs while slowing Purkinje and muscle presystolic conduction at all coupled intervals. Without altering or concurrently slowing down the conduction of late beats (more than 350 msec), MJ 9444 (0.05-0.4 mg/kg) quickens the Purkinje conduction of premature beats (less than 300 msec). Increased dosages (0.4–1.6 mg/kg) cause conduction to slow down constantly. Although in some cases the effective and functional refractory times recovered to control values at larger doses, they were nonetheless shortened. At dosages of 0.4 mg/kg or above, muscle conduction is delayed. The effects of MJ 14030 (0.05-3.2 mg/kg) were not consistent; in three studies, it behaved like MJ 9444, but in two more, it behaved like the parent drug [1].
|
|---|---|
| References | |
| Additional Infomation |
Modecainide is a member of phenols and a member of methoxybenzenes.
|
| Molecular Formula |
C₂₂H₂₈N₂O₃
|
|---|---|
| Molecular Weight |
368.47
|
| Exact Mass |
368.21
|
| CAS # |
81329-71-7
|
| PubChem CID |
54737
|
| Appearance |
White to off-white solid powder
|
| Density |
1.162g/cm3
|
| Boiling Point |
480.6ºC at 760 mmHg
|
| Flash Point |
244.4ºC
|
| Index of Refraction |
1.598
|
| LogP |
4.391
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
27
|
| Complexity |
473
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(NC1=CC=CC=C1CCC2N(C)CCCC2)C3=CC=C(O)C(OC)=C3
|
| Synonyms |
MJ 14030; BMY 40327
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Methanol :≥ 250 mg/mL (~678.48 mM)
DMSO : ~100 mg/mL (~271.39 mM) |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7139 mL | 13.5696 mL | 27.1393 mL | |
| 5 mM | 0.5428 mL | 2.7139 mL | 5.4279 mL | |
| 10 mM | 0.2714 mL | 1.3570 mL | 2.7139 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
